SCHEMBL30075784

SCHEMBL30075784

CCCCOC(=O)N1CC(CS(=O)(=O)CCO)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GBA2 Q9HCG7 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ HRH2 P25021 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ MMP13 P45452 3/20 0.32
▸ MMP3 P08254 2/20 0.32
▸ MMP9 P14780 2/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP8 P22894 1/20 0.32
▸ BCHE P06276 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30075700 0.89 LMNA (0.48) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL29655416 0.80 LMNA (0.50) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30075837 0.80 LMNA (0.44) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL4968757 0.79 LMNA (0.53) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30075860 0.78 LMNA (0.43) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL4968751 0.76 LMNA (0.53) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL23578667 0.76 NR1H2 (0.52) SMN1; SMN2ALDH1A1HPGDGPR119
SCHEMBL30129908 0.75 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30129902 0.75 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30241901 0.75 SMN1; SMN2 (0.46) LMNAPOLBSMN1; SMN2GBA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081515-A1 INHIBITORS OF MUTANT FORMS OF EGFR Blueprint Medicines Corporation (US) 2022-11-02 — — EP disclosed
Send feedback